| Sign In to gain access to subscriptions and/or personal tools. |
An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis
1 Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, NY, USA
* To whom correspondence should be addressed.
Approximately 5-25% of interferon-beta (IFN-beta) treated multiple sclerosis (MS)
patients develop anti-IFN-beta neutralizing antibodies (NAb) but the
patient-specific variables associated with the risk of developing anti-IFN-beta
antibodies are poorly understood. Anti-IFN-beta NAb are a subset of anti-IFN-beta
binding antibodies (BAb) and all patients with NAb generally have high levels of
associated BAb. The purpose of this research was to assess the association between
autoreactive antibodies (ARAB) and the risk of developing anti-IFN-beta BAb in MS
patients. This was a retrospective study that included consecutive patients
diagnosed with clinically definite MS evaluated at our center and considered
appropriate for IFN-beta therapy. The patients were tested for various subtypes of
antiphospholipid antibodies (APLA) including anti-phosphatidylethanolamine (APE),
anti-phosphatidylserine (APS), and anti-cardiolipin (ACA) antibodies, and other
ARAB, antinuclear and anti-neutrophilic cytoplasmic antibodies, anti-thyroid
peroxidase antibodies (ATA), anti-SS-A and anti-SS-B antibodies. BAb levels were
assessed using a commercial binding ELISA assay. A total of 33 patients (mean age:
45.4 years, 85% female) were enrolled; 15 patients were negative and 18 patients
were positive for BAb. APLA or ATA were present in 95% (17 of 18 patients) of
patients positive for BAb. In comparison, APLA or ATA occurred in only 27% (four of
15 patients) of patients in the BAb negative group. The associations between the
occurrence of BAb and the occurrence of high APLA or ATA were significant
( Key Words: antiphospholipid antibody; antithyroid antibody; autoreactive antibody; beta-interferon; binding antibody; multiple sclerosis
First published on April 27, 2007, doi:10.1177/1352458507076968 This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
2=13.4, P<0.001 in Fisher exact
test). The odds ratio for the association was 46.8 (with a 95% confidence interval
range of 4.6-475). No significant correlations were found for other ARAB. The
presence of autoreactive antibodies, particularly APLA and ATA is associated with
increased risk of occurrence of IFN-beta BAb in MS patients on long-term IFN-beta
therapy. Multiple Sclerosis 2007; 00: 000-000. http://msj.sagepub.com
